104 related articles for article (PubMed ID: 29703870)
1. The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island.
Kuan JW; Melaine Michael S
Med J Malaysia; 2018 Apr; 73(2):78-85. PubMed ID: 29703870
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
3. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
4. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island.
Devi BC; Pisani P; Tang TS; Parkin DM
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):482-6. PubMed ID: 15006927
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
6. The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015).
Kuan JW; Su AT; Wahab M; Hamdan A; Hashim J; Kiyu A; Ooi CH
BMC Cancer; 2023 Jun; 23(1):563. PubMed ID: 37337159
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
8. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
9. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of clonal Philadelphia-negative cytogenetic abnormalities in a large cohort of chronic myeloid leukaemia.
Chen X; Zheng J; Liang K; He Y; Du W; Li J; Liu W; Hu Y; Huang S; Yao J
Intern Med J; 2018 Apr; 48(4):439-444. PubMed ID: 28636094
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
12. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
13. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
15. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
17. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.
Kuan JW; Su AT; Tay SP; Fong IL; Kubota S; Su'ut L; Osato M; Sashida G
Int J Hematol; 2020 Feb; 111(2):217-224. PubMed ID: 31707540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
